JAK1 and COVID-19: Considering that fedratinib/pacitinib spare antigen-specific T-cell activity and minimize opportunistic infections, selective JAK2 inhibitors could be initially trialed rather than broader JAK1/2 inhibitors in the treatment of COVID-19 CRS (170).